We are live on
!
Find out more
IHAM
Integral Health Asset Management Portfolio holdings
AUM
$2.09B
1-Year Est. Return
112.84%
This Fund
S&P 500
This Quarter
Est. Return
-6.53%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$384M
AUM Growth
+$22.9M
(+6.3%)
Cap. Flow
+$49.3M
Cap. Flow
% of AUM
12.82%
Top 10 Holdings %
Top 10 Hldgs %
35.81%
Holding
89
New
18
Increased
39
Reduced
11
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Elevance Health
ELV
|
+$9.14M |
| 2 |
CRISPR Therapeutics
CRSP
|
+$7.54M |
| 3 |
Guardant Health
GH
|
+$6.84M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$6.76M |
| 5 |
Merck
MRK
|
+$5.91M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
McKesson
MCK
|
+$13.7M |
| 2 |
Abbott
ABT
|
+$9.85M |
| 3 |
Fate Therapeutics
FATE
|
+$7.61M |
| 4 |
AbbVie
ABBV
|
+$6.77M |
| 5 |
Labcorp
LH
|
+$6.28M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Arrowhead Research
ARWR
$12.6B
| – | – |
-50,000
| Closed | -$3.31M |
|
77
CALL
BridgeBio Pharma
BBIO
$16.6B
| – | – |
-150,000
| Closed | -$2.5M |
|
78
Edwards Lifesciences
EW
$53.5B
| – | – |
-45,000
| Closed | -$5.83M |
|
|
79
Fate Therapeutics
FATE
$325M
| – | – |
-130,000
| Closed | -$7.61M |
|
80
GSK
GSK
$101B
| – | – |
-80,000
| Closed | -$4.41M |
|
|
81
Labcorp
LH
$26.1B
| – | – |
-23,280
| Closed | -$6.28M |
|
82
Lexicon Pharmaceuticals
LXRX
$1.07B
| – | – |
-200,000
| Closed | -$788K |
|
83
Lyell Immunopharma
LYEL
$354M
| – | – |
-7,000
| Closed | -$1.08M |
|
|
MASI
84
DELISTED
Masimo
MASI
| – | – |
-10,000
| Closed | -$2.93M |
|
|
85
McKesson
MCK
$104B
| – | – |
-55,000
| Closed | -$13.7M |
|
86
MacroGenics
MGNX
$256M
| – | – |
-130,000
| Closed | -$2.09M |
|
|
IMGN
87
DELISTED
Immunogen Inc
IMGN
| – | – |
-250,000
| Closed | -$1.85M |
|
|
MYOV
88
DELISTED
Myovant Sciences Ltd.
MYOV
| – | – |
-25,000
| Closed | -$389K |
|
|
HZNP
89
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| – | – |
-30,000
| Closed | -$3.23M |
|
Similar funds
CL
ACM
ACG
NSUP
TP
ACP
TA
AG
Integral Health Asset Management's Q1 2022 Portfolio in Review
As of Q1 2022, Integral Health Asset Management held 89 positions worth $384M, up 6.3% from $361M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Integral Health Asset Management deployed $49.3M of net new capital in Q1 2022, opening 18 new positions and adding to 39 existing holdings. Its largest new stake was CRISPR Therapeutics: 120,000 shares worth $7.53M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier.
On the sell side, the largest reduction was Centene, an estimated $6.15M trimmed.
- Integral Health Asset Management's largest Q1 2022 buy was CRISPR Therapeutics: 120,000 shares worth $7.53M.
- Integral Health Asset Management added most to Elevance Health in Q1 2022, an estimated $9.14M increase.
- Integral Health Asset Management's biggest Q1 2022 reduction was Centene, cutting an estimated $6.15M.
- Integral Health Asset Management fully exited McKesson in Q1 2022, selling an estimated $13.7M.
- Integral Health Asset Management's ten largest holdings make up 36% of its $384M portfolio in Q1 2022.
- Integral Health Asset Management opened 18 new positions and closed 18 in Q1 2022.
- Integral Health Asset Management's portfolio value rose 6.3% quarter-over-quarter to $384M.
Based on Integral Health Asset Management's 13F filing for Q1 2022, filed 12 May 2022.